An Investigational Product (IP) refers to a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial. This includes products with existing marketing authorization that are being studied for new uses, formulations, or indications, as well as those not yet approved for marketing.
IPs are central to clinical research, as they are the interventions being evaluated for safety and efficacy. They undergo rigorous testing and must be manufactured, handled, and stored according to Good Manufacturing Practice (GMP) guidelines to ensure quality and consistency throughout the clinical trial process.
The term ‘Investigational Product (IP)’ is crucial in clinical research as it provides a clear and standardized way to refer to the substance being studied. This terminology helps ensure compliance with regulatory guidelines and facilitates effective communication among researchers, sponsors, and regulatory bodies throughout the clinical trial process.
Understanding the concept of IP is essential for proper handling, documentation, and accountability of the study drug. It emphasizes the experimental nature of the product and the need for stringent protocols in its use, helping to maintain the integrity of the research and protect the safety of study participants.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant